AI Health Index
Product Change Log

What Changed at bioAffinity Technologies

Every material change AI Health Index has tracked at bioAffinity Technologies: new modules, model and architecture updates, clinical evidence, regulatory status, security certifications, and integration depth. Each entry states what changed, cites its source, and carries our read on what it means for a buyer. The graded assessment of this vendor across all fifteen capability axes sits on its index profile.

Funding rounds, valuations, and awards are not product changes and are not logged here. Acquisitions appear only where there is direct product impact.

Impact
Type
1 entry
Showing changes for bioAffinity Technologies only.Show the full log

September 2026

B
HighVerified
Product / capability

bioAffinity extended CyPath Lung from early detection into surveillance of lung cancer survivors. The noninvasive sputum test is now positioned to complement CT imaging when monitoring for recurrence and when evaluating new or changing pulmonary nodules in patients who have completed curative intent treatment.

Our read

Surveillance is a larger and more repetitive population than initial screening, so this is a meaningful widening of where the test can sit in a pathway. The specific job is risk stratification when imaging is equivocal, which is the moment a pulmonologist currently has to choose between watchful waiting and an invasive procedure on incomplete information.

Related axis: Setting and Specialty CoverageRegulatory filingView source